Status:
UNKNOWN
Effects of Oral Glutamine Supplementation on Insulin Resistance and Functional Intestinal Disorders in Obese Patients.
Lead Sponsor:
University Hospital, Rouen
Conditions:
Obesity
Insulin Resistance
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Obesity, which has a prevalence at 15% in France, is a major public health concern. Altered glycemic control and irritable bowel syndrome (IBS) are frequently observed in obese patients and lead to re...
Eligibility Criteria
Inclusion
- Patients aged from 18 to 65 years
- Patient with h grade II or III obesity (body mass index equal or higher than 35 kg/m2)
- Patient with insulino-resistance (fasting glycaemia ≥ 1g/l et \< 1.26 g/l)
- Patient with irritable bowel syndrome (Rome IV criteria ≥ 2)
Exclusion
- Patient with Known liver insufficiency (prothrombin time \< 70%)
- Patient with Known kidney failure (GFR \< 60 ml/mn)
- Patient with Known intestinal diseases such as inflammatory bowel diseases
- Vomiting patients (≥ 1/ day) during the last 4 weeks
- Patient Previously received bariatric surgery or digestive surgery
- Patient Using laxatives or protein powder during the 4 last weeks
- On going Pregnancy
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04883515
Start Date
June 1 2021
End Date
September 1 2024
Last Update
May 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rouen University Hospital
Rouen, France, 76031